News and Events
Latest News
Media Advisory
Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies.
Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020.
Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
TBC
Generic name
etonogestrel
Manufacturer
Merck Canada Inc.
Indication(s)
Prevention of pregnancy
Project Number
SR0648-000
Call for patient input
2020-05-06
Patient input deadlin...
View all News
Upcoming Events
The magnitude of the COVID-19 pandemic globally is generating considerable interest in options to prevent infection and minimize the impact if infection occurs. Pre-exposure prophylaxis and post-exposure treatment with a group of drugs called antivirals, sometimes in combination with an antibiotic, have been the subject of public debate and, at ...
View all Events
